Display options
Share it on

J Clin Med. 2014 Oct 15;3(4):1105-23. doi: 10.3390/jcm3041105.

Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells.

Journal of clinical medicine

Kwong-Man Ng, Cheuk-Yiu Law, Hung-Fat Tse

Affiliations

  1. Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  2. Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  3. Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  4. Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  5. Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  6. Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China. [email protected].
  7. Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine, the University of Hong Kong and Guangzhou Institutes of Biomedicine and Health, Hong Kong SAR, China. [email protected].
  8. Shenzhen Institutes of Research and Innovation, the University of Hong Kong, Hong Kong SAR, China. [email protected].

PMID: 26237594 PMCID: PMC4470173 DOI: 10.3390/jcm3041105

Abstract

The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail.

Keywords: drug testing; modeling of inherited cardiac disorder; patient-specific-iPSCs-derived cardiomyocytes; regenerative medicine; toxicology studies

References

  1. J Vis Exp. 2012 Oct 31;(68):null - PubMed
  2. Blood. 2013 Apr 4;121(14):e98-107 - PubMed
  3. Am J Hum Genet. 2001 Dec;69(6):1378-84 - PubMed
  4. J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):246-56 - PubMed
  5. J Cell Mol Med. 2012 Mar;16(3):468-82 - PubMed
  6. Circulation. 2006 Apr 11;113(14):1807-16 - PubMed
  7. Nat Biotechnol. 2008 Jan;26(1):101-6 - PubMed
  8. Cell Stem Cell. 2011 Feb 4;8(2):228-40 - PubMed
  9. Circ Res. 2006 May 12;98(9):1151-8 - PubMed
  10. Pflugers Arch. 2014 Sep;466(9):1831-44 - PubMed
  11. Wien Med Wochenschr. 2012 Jul;162(13-14):297-301 - PubMed
  12. J Mol Cell Cardiol. 1999 Nov;31(11):2063-76 - PubMed
  13. J Am Coll Cardiol. 2005 Apr 5;45(7):969-81 - PubMed
  14. Sci Transl Med. 2012 Apr 18;4(130):130ra47 - PubMed
  15. EMBO Mol Med. 2012 Mar;4(3):180-91 - PubMed
  16. Nat Biotechnol. 2007 Sep;25(9):1015-24 - PubMed
  17. Stem Cell Rev. 2011 Nov;7(4):976-86 - PubMed
  18. Nature. 2008 May 22;453(7194):524-8 - PubMed
  19. Neurosci Lett. 2012 May 10;516(1):9-14 - PubMed
  20. J Anat. 2002 Mar;200(Pt 3):233-42 - PubMed
  21. J Am Coll Cardiol. 1998 Jan;31(1):186-94 - PubMed
  22. Science. 2009 Apr 3;324(5923):98-102 - PubMed
  23. Hum Mol Genet. 2012 Jan 1;21(1):32-45 - PubMed
  24. J Appl Toxicol. 2011 Apr;31(3):191-205 - PubMed
  25. Stem Cells. 2010 Jan;28(1):64-74 - PubMed
  26. Nature. 2011 Mar 10;471(7337):225-9 - PubMed
  27. Int J Stem Cells. 2012 Nov;5(2):140-5 - PubMed
  28. Stem Cell Rev. 2013 Aug;9(4):451-60 - PubMed
  29. PLoS One. 2008 Jul 09;3(7):e2642 - PubMed
  30. J Biotechnol. 2010 Oct 1;150(1):175-81 - PubMed
  31. Stem Cells. 2010 Oct;28(10):1728-40 - PubMed
  32. Cardiovasc Res. 2008 Jul 1;79(1):109-17 - PubMed
  33. J Clin Invest. 1999 Dec;104(12):1683-92 - PubMed
  34. Int J Cardiol. 2013 Oct 15;168(6):5277-86 - PubMed
  35. Pediatr Cardiol. 2013 Feb;34(2):467-70 - PubMed
  36. Curr Opin Cardiol. 2011 Mar;26(2):155-64 - PubMed
  37. Cell. 2006 Aug 25;126(4):663-76 - PubMed
  38. J Theor Biol. 2010 Aug 7;265(3):433-42 - PubMed
  39. Circulation. 2008 Nov 25;118(22):2225-34 - PubMed
  40. Circ Res. 2011 Jul 22;109(3):255-61 - PubMed
  41. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348-62 - PubMed
  42. Stem Cells. 2005 Jun-Jul;23(6):772-80 - PubMed
  43. Stem Cells Dev. 2012 Apr 10;21(6):977-86 - PubMed
  44. N Engl J Med. 2010 Oct 7;363(15):1397-409 - PubMed
  45. Methods Mol Biol. 2013;1036:81-8 - PubMed
  46. Toxicol Pathol. 2006;34(1):81-90 - PubMed
  47. Nat Protoc. 2012 Dec;7(12):2080-9 - PubMed
  48. Prog Cardiovasc Dis. 2008 Jul-Aug;51(1):23-30 - PubMed
  49. Nat Rev Drug Discov. 2004 Aug;3(8):711-5 - PubMed
  50. J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):277-86 - PubMed
  51. Science. 2007 Dec 21;318(5858):1917-20 - PubMed
  52. Circ Res. 2004 Mar 5;94(4):471-7 - PubMed
  53. Biochem Biophys Res Commun. 2009 Sep 25;387(3):482-8 - PubMed
  54. Cell Reprogram. 2010 Dec;12(6):665-78 - PubMed
  55. Bosn J Basic Med Sci. 2009 May;9(2):107-10 - PubMed
  56. Pharmacol Ther. 2008 Aug;119(2):152-9 - PubMed
  57. Cell Physiol Biochem. 2011;28(4):579-92 - PubMed
  58. Hum Mol Genet. 2013 Apr 1;22(7):1395-403 - PubMed
  59. Cell Stem Cell. 2013 Jan 3;12(1):101-13 - PubMed
  60. Science. 1996 May 3;272(5262):731-4 - PubMed
  61. Circulation. 2001 Jan 16;103(2):196-200 - PubMed
  62. Eur Heart J. 1995 Dec;16 Suppl O:2-4 - PubMed
  63. Stem Cell Res. 2007 Oct;1(1):9-24 - PubMed
  64. Cardiovasc Res. 2005 Aug 15;67(3):379-87 - PubMed
  65. Circ Res. 2005 May 27;96(10):e77-82 - PubMed
  66. Nat Protoc. 2013 Jan;8(1):162-75 - PubMed
  67. Stem Cells. 2009 Mar;27(3):543-9 - PubMed
  68. J Clin Invest. 1999 Aug;104(4):469-81 - PubMed
  69. Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1848-57 - PubMed
  70. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15432-7 - PubMed
  71. Cardiovasc Res. 2010 Jul 1;87(1):40-9 - PubMed
  72. J Cardiovasc Transl Res. 2013 Feb;6(1):1-9 - PubMed
  73. Stem Cells. 2009 Nov;27(11):2667-74 - PubMed
  74. Dis Model Mech. 2012 Mar;5(2):220-30 - PubMed
  75. Mol Pharm. 2011 Oct 3;8(5):1602-10 - PubMed
  76. Cardiovasc Res. 2003 Apr 1;58(1):32-45 - PubMed
  77. Cell. 2007 Nov 30;131(5):861-72 - PubMed
  78. Cell. 2004 Oct 1;119(1):19-31 - PubMed
  79. Ann Intern Med. 2005 Jul 19;143(2):108-15 - PubMed
  80. Eur Heart J. 2011 Apr;32(8):952-62 - PubMed
  81. Adv Exp Med Biol. 2012;740:1145-74 - PubMed
  82. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64 - PubMed
  83. Nature. 2011 Mar 10;471(7337):230-4 - PubMed
  84. Nat Clin Pract Cardiovasc Med. 2008 Mar;5(3):158-68 - PubMed
  85. Circulation. 2006 Sep 5;114(10):1012-9 - PubMed

Publication Types